Looking at the world data you would be excused to think that the monkeypox virus #3MXP was under control, but looking at individual countries you can see that most countries are not reporting data (“doing a McGowan”). There is no way they could all have had no new cases for 3 to 4 days at the same time.
So to get a better idea I picked on some countries like the UK to see if I could get any updates myself. The “Our World in Data” site says the UK has had 575 cases. I found this posted 3 hours ago.
“A further 219 cases of monkeypox have been detected in the UK, bringing the nationwide total to 793.” (sic)
https://www.independent.co.uk/news/health/monkeypox-cases-uk-rise-transmission-b2105839.html
And it gets worse. The UK Government is offering the small pox vaccine to people (I believe close contacts) to help control the outbreak of the virus. I believe Spain and Portugal are doing the same.
In the UK most who are infected are young men but 4 women are also infected, and I believe some children. It does have a sexual connotation but it seems to be spread much faster than the usual West African monkeypox.
This is the WHO a day ago and they are always behind. So there were 21-3 cases in 42 countries whereas “our World in Data” last reported 2680, so the WHO is way off the mark. I wonder what the true figures are. So what I am saying is that the situation is far worse than has been reported and I still feel that this monkeypox virus outbreak is far from being under control. I would not be surprised in the WHO declares this a worldwide issue/pandemic in the next month.
This is interesting. The FDA had approved a new vaccine for small pox and monkeypox in late 2019.
From there (Note the date):
“September 24, 2019: FDA announced the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease. Jynneos will be available for those determined to be at high risk of either smallpox or monkeypox infection. This vaccine is also part of the Strategic National Stockpile (SNS), the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency that is severe enough to cause local supplies to be depleted. The availability of this vaccine in the SNS will help ensure that the vaccine is accessible in the U.S. if needed.”